ACVIM consensus guidelines for the diagnosis and treatment of myxomatous mitral valve disease in dogsBruce W. Keene, Masami Uechi, Clarke E. Atkins et al.|Journal of Veterinary Internal Medicine|2019Cited by 810
Effect of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease and Cardiomegaly: The EPIC Study—A Randomized Clinical TrialAdrian Boswood, Philip Watson, María Josefa Fernández del Palacio et al.|Journal of Veterinary Internal Medicine|2016Cited by 318
Prediction of first onset of congestive heart failure in dogs with degenerative mitral valve disease: The PREDICT cohort studyCaryn Reynolds, Mark A. Oyama, Dorothy Cimino Brown et al.|Journal of Veterinary Cardiology|2012Cited by 126
Utility of plasma N-terminal pro-brain natriuretic peptide (NT-proBNP) to distinguish between congestive heart failure and non-cardiac causes of acute dyspnea in catsPhilip R. Fox, Daniel F. Hogan, N. Sydney Möise et al.|Journal of Veterinary Cardiology|2009Cited by 113
Multicenter Evaluation of Plasma N-Terminal Probrain Natriuretic Peptide (NT-pro BNP) as a Biochemical Screening Test for Asymptomatic (occult) Cardiomyopathy in CatsPhilip R. Fox, Mark A. Oyama, Clarke E. Atkins et al.|Journal of Veterinary Internal Medicine|2011Cited by 100